Matt Rosales

453 total citations
14 papers, 150 citations indexed

About

Matt Rosales is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Matt Rosales has authored 14 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Matt Rosales's work include Acute Myeloid Leukemia Research (7 papers), Prostate Cancer Treatment and Research (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Matt Rosales is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Prostate Cancer Treatment and Research (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Matt Rosales collaborates with scholars based in United States, Italy and Spain. Matt Rosales's co-authors include Mark J. Levis, Erkut Bahceci, Alexander E. Perl, Jason E. Hill, Catherine C. Smith, Mehdi Hamadani, Steven M. Devine, Brent R. Logan, Mary M. Horowitz and Nasser H. Hanna and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Matt Rosales

12 papers receiving 148 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matt Rosales United States 6 122 63 38 21 13 14 150
Gabriela Borsaru Romania 7 111 0.9× 105 1.7× 28 0.7× 9 0.4× 9 0.7× 11 169
Keren Machol United States 6 64 0.5× 58 0.9× 17 0.4× 27 1.3× 5 0.4× 11 123
Marlen Metzner United Kingdom 5 87 0.7× 29 0.5× 20 0.5× 16 0.8× 26 2.0× 15 123
Eveline S. de Bont Netherlands 5 72 0.6× 36 0.6× 47 1.2× 28 1.3× 3 0.2× 16 117
Mariangela Greco Italy 6 85 0.7× 102 1.6× 30 0.8× 29 1.4× 3 0.2× 14 148
Sara Duarte Portugal 5 70 0.6× 46 0.7× 14 0.4× 12 0.6× 4 0.3× 10 140
Ingrid Furlan Germany 6 89 0.7× 69 1.1× 24 0.6× 17 0.8× 10 0.8× 13 164
Linhua Yang China 8 136 1.1× 82 1.3× 30 0.8× 4 0.2× 6 0.5× 45 195
J A Castillejo Spain 6 108 0.9× 103 1.6× 21 0.6× 36 1.7× 14 1.1× 7 209
Faisal Basheer Pakistan 5 86 0.7× 121 1.9× 12 0.3× 8 0.4× 5 0.4× 22 174

Countries citing papers authored by Matt Rosales

Since Specialization
Citations

This map shows the geographic impact of Matt Rosales's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt Rosales with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt Rosales more than expected).

Fields of papers citing papers by Matt Rosales

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt Rosales. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt Rosales. The network helps show where Matt Rosales may publish in the future.

Co-authorship network of co-authors of Matt Rosales

This figure shows the co-authorship network connecting the top 25 collaborators of Matt Rosales. A scholar is included among the top collaborators of Matt Rosales based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matt Rosales. Matt Rosales is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Giorgi, Ugo De, Stephen J. Freedland, Antti Rannikko, et al.. (2025). Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK. Prostate Cancer and Prostatic Diseases. 29(1). 198–201. 1 indexed citations
2.
3.
Shore, Neal D., Murilo Luz, Ugo De Giorgi, et al.. (2025). Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 394(6). 563–575. 1 indexed citations
4.
Freedland, Stephen J., Paul Sieber, Martin Gleave, et al.. (2024). Enzalutamide combination treatment (tx) suspension in men with high-risk biochemically recurrent (BCR) prostate cancer: Outcomes from EMBARK.. Journal of Clinical Oncology. 42(4_suppl). 156–156.
5.
Shore, Neal D., Paul Sieber, Martin Gleave, et al.. (2024). Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.. Journal of Clinical Oncology. 42(4_suppl). 15–15. 1 indexed citations
6.
Adra, Nabil, David J. Vaughn, Lawrence H. Einhorn, et al.. (2022). A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors. Investigational New Drugs. 40(5). 1087–1094. 17 indexed citations
7.
Smith, Catherine C., Mark J. Levis, Alexander E. Perl, et al.. (2022). Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Advances. 6(7). 2144–2155. 47 indexed citations
8.
9.
Adra, Nabil, David J. Vaughn, Lawrence H. Einhorn, et al.. (2020). A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors.. Journal of Clinical Oncology. 38(6_suppl). TPS424–TPS424. 5 indexed citations
10.
Smith, Catherine C., Mark J. Levis, Alexander E. Perl, et al.. (2019). Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial. Blood. 134(Supplement_1). 14–14. 17 indexed citations
11.
Levis, Mark J., Mehdi Hamadani, Brent R. Logan, et al.. (2019). BMT CTN Protocol 1506: A Phase 3 Trial of Gilteritinib As Maintenance Therapy after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD+ AML. Blood. 134(Supplement_1). 4602–4602. 25 indexed citations
12.
Levis, Mark J., Alexander E. Perl, Giovanni Martinelli, et al.. (2019). Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.. Journal of Clinical Oncology. 37(15_suppl). 7000–7000. 5 indexed citations
13.
14.
Levis, Mark J., Mehdi Hamadani, Brent R. Logan, et al.. (2018). A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.. Journal of Clinical Oncology. 36(15_suppl). TPS7075–TPS7075. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriela Borsaru Breakdown of academic impact, for papers by Keren Machol Breakdown of academic impact, for papers by Marlen Metzner Breakdown of academic impact, for papers by Eveline S. de Bont Breakdown of academic impact, for papers by Mariangela Greco Breakdown of academic impact, for papers by Sara Duarte Breakdown of academic impact, for papers by Ingrid Furlan Breakdown of academic impact, for papers by Linhua Yang Breakdown of academic impact, for papers by J A Castillejo Breakdown of academic impact, for papers by Faisal Basheer
Rankless by CCL
2026